| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.04. | 2cureX AB: 2cureX AB completes oversubscribed directed issue | 116 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") today announces that it has successfully completed an oversubscribed directed share issue of 6,800,000 shares to a select group of international investors (the... ► Artikel lesen | |
| 27.02. | 2cureX AB receives observation status | 208 | GlobeNewswire | Yesterday, February 26, 2026, 2cureX AB (the "Company") disclosed its annual financial statement release for 2025 with information on the Company's financial situation.
According to item 6.3.1... ► Artikel lesen | |
| 26.02. | 2cureX AB: 2cureX AB (publ) publishes Interim Report for the Second Half of 2025 | 147 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") hereby publishes its interim report for the second half of 2025 (July 1 - December 31, 2025).
The second half of 2025 has been characterised by continued execution... ► Artikel lesen | |
| 21.08.25 | 2cureX AB: 2cureX AB ("2cureX") hereby publishes the interim report for the first half year of 2025. | 369 | GlobeNewswire (Europe) | The interim report is available as an attached document as well as on the company's website (https://www.2curex.se). A short summary of the report follows below.
CEO Nat Hutley comments:"EXECUTION.... ► Artikel lesen | |
| 2CUREX Aktie jetzt für 0€ handeln | |||||
| 01.07.25 | 2cureX AB: 2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG. | 316 | GlobeNewswire (Europe) | PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could align the scientific and commercial strengths of both companies... ► Artikel lesen | |
| 20.05.25 | 2cureX AB: 2cureX Conducts First Direct-to-Patient IndiTreat Test Under "Operation Twin Code" Strategy | 384 | GlobeNewswire (Europe) | 2cureX AB (Ticker: 2CUREX) is proud to announce a historic commercial milestone: the company has successfully sold and initiated delivery of its first IndiTreat® test through its direct-to-patient channel.... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,035 | -13,30 % | MEDIGENE AG zeigt erneute innere Stärke | ||
| EPIGENOMICS | 0,930 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| BIOFRONTERA | 2,420 | +1,26 % | PTA-HV: Biofrontera AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Biofrontera AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Biofrontera AG: Einladung zur ordentlichen Hauptversammlung
Leverkusen... ► Artikel lesen | |
| NANOREPRO | 1,490 | +1,36 % | NanoRepro: Guter Deal | Das ist offensichtlich: Gemessen an den nahezu identischen Kurszielen von 4,50 Euro (GBC) und 4,30 Euro (NuWays) lässt NanoRepro gegenwärtig viel Raum im Chart ungenutzt. So pendelt die Notiz seit Monaten... ► Artikel lesen | |
| BIOXXMED | 0,820 | +3,80 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| OCUGEN | 1,256 | 0,00 % | Ocugen Aktie explodiert nach unten: Wie tief geht es noch? | ||
| CLINUVEL | 5,626 | -0,25 % | CLINUVEL PHARMACEUTICALS LIMITED: Notification regarding unquoted securities - CUV | ||
| SANGAMO THERAPEUTICS | 0,110 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,360 | 0,00 % | COSCIENS Biopharma Inc. GAAP EPS of -$0.06, revenue of $1.9M | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,500 | 0,00 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| SAREPTA THERAPEUTICS | 16,100 | -1,23 % | Sarepta tumbles as its gene therapy sales decline further | ||
| IBIO | 1,437 | +5,12 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen | |
| ASEP MEDICAL | 0,075 | 0,00 % | XFRA JJ80: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILASEP MEDICAL HOLDINGS... ► Artikel lesen |